BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cotter TG, Paul S, Sandıkçı B, Couri T, Bodzin AS, Little EC, Sundaram V, Charlton M. Improved Graft Survival After Liver Transplantation for Recipients With Hepatitis C Virus in the Direct-Acting Antiviral Era. Liver Transpl 2019;25:598-609. [PMID: 30716208 DOI: 10.1002/lt.25424] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 16.0] [Reference Citation Analysis]
Number Citing Articles
1 Junger H, Knoppke B, Weigand K, Evert K, Brennfleck FW, Melter M, Schlitt HJ, Brunner SM. Living Donor Liver Transplantation From Hepatitis C-Infected Donor to Hepatitis C-Infected Recipient. Hepatology 2020;72:1148-51. [PMID: 32064653 DOI: 10.1002/hep.31185] [Reference Citation Analysis]
2 Spearman CW, Dusheiko GM, Hellard M, Sonderup M. Hepatitis C. Lancet. 2019;394:1451-1466. [PMID: 31 DOI: 10.1016/s0140-6736(19)32320-7] [Cited by in Crossref: 108] [Cited by in F6Publishing: 56] [Article Influence: 2.3] [Reference Citation Analysis]
3 Cotter TG, Jensen DM. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy. Drug Des Devel Ther 2019;13:2565-77. [PMID: 31534310 DOI: 10.2147/DDDT.S172512] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
4 Cotter TG, Sandıkçı B, Paul S, Gampa A, Wang J, Te H, Pillai A, Reddy KG, Sabato D, Little EC, Sundaram V, Fung J, Lucey MR, Charlton M. Liver transplantation for alcoholic hepatitis in the United States: Excellent outcomes with profound temporal and geographic variation in frequency. Am J Transplant 2021;21:1039-55. [DOI: 10.1111/ajt.16143] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
5 Goldberg D, Mantero A, Newcomb C, Delgado C, Forde K, Kaplan D, John B, Nuchovich N, Dominguez B, Emanuel E, Reese PP. Development and Validation of a Model to Predict Long-Term Survival After Liver Transplantation. Liver Transpl 2021;27:797-807. [PMID: 33540489 DOI: 10.1002/lt.26002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Yu M, Chen P, Dai C, Hu T, Huang C, Huang Y, Hung C, Lin C, Liu C, Liu C, Peng C, Lin H, Kao J, Chuang W. 2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations. Journal of the Formosan Medical Association 2020;119:1135-57. [DOI: 10.1016/j.jfma.2020.04.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 12.0] [Reference Citation Analysis]
7 Khan AS, Adams N, Vachharajani N, Dageforde L, Wellen J, Shenoy S, Crippin JS, Doyle MB, Chapman WC. Liver transplantation for hepatitis C patients in the era of direct-acting antiviral treatment: A retrospective cohort study. Int J Surg 2020;75:84-90. [PMID: 32014598 DOI: 10.1016/j.ijsu.2020.01.145] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
8 Booth IA, Clark JE, LaMattina JC, Barth RN, Haririan A, Ravichandran BR. The Impact of Treatment Delay on Hepatitis C Liver Transplant Outcomes. J Pharm Pract 2021;:8971900211034261. [PMID: 34289722 DOI: 10.1177/08971900211034261] [Reference Citation Analysis]
9 Martin EF. Paradigm Shift in Utilization of Livers from Hepatitis C-Viremic Donors into Hepatitis C Virus-Negative Patients. Clin Liver Dis 2021;25:195-207. [PMID: 33978579 DOI: 10.1016/j.cld.2020.08.009] [Reference Citation Analysis]
10 Caballero-Marcos A, Romero-Cristóbal M, Puerto M, Fernández-Yunquera A, Dieguez L, Navarrete C, Clemente A, Diaz-Fontenla F, Catalán P, Rincón D, López-Baena JÁ, Bañares Cañizares R, Salcedo M. HCV eradication in recurrent hepatitis C after liver transplantation normalizes enhanced endothelial activation. Transpl Int 2021. [PMID: 34346111 DOI: 10.1111/tri.14000] [Reference Citation Analysis]
11 Delman AM, Ammann AM, Shah SA. The current status of virus-positive liver transplantation. Curr Opin Organ Transplant 2021;26:160-7. [PMID: 33595981 DOI: 10.1097/MOT.0000000000000850] [Reference Citation Analysis]
12 Cuesta-Sancho S, Márquez-Coello M, Illanes-Álvarez F, Márquez-Ruiz D, Arizcorreta A, Galán-Sánchez F, Montiel N, Rodriguez-Iglesias M, Girón-González JA. Hepatitis C: Problems to extinction and residual hepatic and extrahepatic lesions after sustained virological response. World J Hepatol 2022; 14(1): 62-79 [DOI: 10.4254/wjh.v14.i1.62] [Reference Citation Analysis]
13 Raasikh T, Jamali T, Flores A, Cotton RT, Ramanathan V, Tan HP, Hernaez R. Systematic review: hepatitis C viraemic allografts to hepatitis C-negative recipients in solid organ transplantation. Aliment Pharmacol Ther 2021;54:571-82. [PMID: 34265111 DOI: 10.1111/apt.16508] [Reference Citation Analysis]
14 Cotter TG, Wang J, Lieber SR, Odenwald MA, Rich NE, Marrero JA, Singal AG, Mitchell MC, Aronsohn A, Charlton M, Fung J. "Raising HOPE": Improved Outcomes for HIV/HCV-coinfected Liver Transplant Recipients in the Direct-acting Antiviral Era. Transplant Direct 2021;7:e707. [PMID: 34124343 DOI: 10.1097/TXD.0000000000001154] [Reference Citation Analysis]
15 Crismale JF, Khalid M, Bhansali A, De Boccardo G, Khaim R, Florman SS, Shapiro R, Schiano TD. Liver, simultaneous liver-kidney, and kidney transplantation from hepatitis C-positive donors in hepatitis C-negative recipients: A single-center study. Clin Transplant 2020;34:e13761. [PMID: 31808193 DOI: 10.1111/ctr.13761] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
16 Crismale JF, Ahmad J. Expanding the donor pool: Hepatitis C, hepatitis B and human immunodeficiency virus-positive donors in liver transplantation. World J Gastroenterol 2019; 25(47): 6799-6812 [PMID: 31885421 DOI: 10.3748/wjg.v25.i47.6799] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
17 Kim ST, Hadaya J, Tran Z, Iyengar A, Williamson CG, Rabkin D, Benharash P. Association of donor hypertension and outcomes in orthotopic heart transplantation. Clin Transplant 2021;:e14484. [PMID: 34515371 DOI: 10.1111/ctr.14484] [Reference Citation Analysis]
18 Holzner ML, Florman S, Schwartz ME, Tabrizian P. Outcomes of liver transplantation for nonalcoholic steatohepatitis-associated hepatocellular carcinoma. HPB (Oxford) 2021:S1365-182X(21)01587-2. [PMID: 34544629 DOI: 10.1016/j.hpb.2021.08.943] [Reference Citation Analysis]
19 Altshuler PJ, Dang H, Frank AM, Shah AP, Glorioso J, Zhan T, Rios Diaz A, Shaheen O, Ramirez CB, Maley WR, Bodzin AS. Evaluating Outcomes Related to Donor and Recipient Metabolic Environment: Macrosteatotic Allografts and Nonalcoholic Steatohepatitis. Liver Transpl 2021. [PMID: 34564931 DOI: 10.1002/lt.26313] [Reference Citation Analysis]
20 Jiménez-Romero C, Justo I, Marcacuzco A, García V, Manrique A, García-Sesma Á, Calvo J, Fernández I, Martín-Arriscado C, Caso Ó. Safe use of livers from deceased donors older than 70 years in recipients with HCV cirrhosis treated with direct-action antivirals. Retrospective cohort study. Int J Surg 2021;91:105981. [PMID: 34098075 DOI: 10.1016/j.ijsu.2021.105981] [Reference Citation Analysis]
21 Ismail MS, Mohamed I, Polychronopoulou E, Goss JA, Kuo YF, Kanwal F, Jalal PK. Outcomes in the Era of Interferon-Free Direct-Acting Antiviral Therapy After Liver Transplantation in Patients with Hepatitis C Virus and Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:701-11. [PMID: 34235107 DOI: 10.2147/JHC.S309354] [Reference Citation Analysis]
22 Danford CJ, Redman JS, Alonso D. Hepatitis C-positive liver transplantation: outcomes and current practice. Curr Opin Organ Transplant 2021;26:115-20. [PMID: 33595978 DOI: 10.1097/MOT.0000000000000848] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Cotter TG, Ayoub F, King AC, Reddy KG, Charlton M. Practice Habits, Knowledge, and Attitudes of Hepatologists to Alcohol Use Disorder Medication: Sobering Gaps and Opportunities. Transplant Direct 2020;6:e603. [PMID: 33134483 DOI: 10.1097/TXD.0000000000001054] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Trilianos P, Tsangaris A, Tawadros A, Deshpande V, Pyrsopoulos N. The Reliability of Fibro-test in Staging Orthotopic Liver Transplant Recipients with Recurrent Hepatitis C. J Clin Transl Hepatol 2020;8:9-12. [PMID: 32274340 DOI: 10.14218/JCTH.2019.00038] [Reference Citation Analysis]
25 Krassenburg LAP, Maan R, Ramji A, Manns MP, Cornberg M, Wedemeyer H, de Knegt RJ, Hansen BE, Janssen HLA, de Man RA, Feld JJ, van der Meer AJ. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. J Hepatol 2021;74:1053-63. [PMID: 33242501 DOI: 10.1016/j.jhep.2020.11.021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
26 Cotter TG, Minhem M, Wang J, Peeraphatdit T, Ayoub F, Pillai A, Hernandez-Alejandro R, di Sabato D, Charlton M. Living Donor Liver Transplantation in the United States: Evolution of Frequency, Outcomes, Center Volumes, and Factors Associated With Outcomes. Liver Transpl 2021;27:1019-31. [PMID: 33619854 DOI: 10.1002/lt.26029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Goldberg D, Mantero A, Newcomb C, Delgado C, Forde KA, Kaplan DE, John B, Nuchovich N, Dominguez B, Emanuel E, Reese PP. Predicting survival after liver transplantation in patients with hepatocellular carcinoma using the LiTES-HCC score. J Hepatol. 2021;74:1398-1406. [PMID: 33453328 DOI: 10.1016/j.jhep.2020.12.021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
28 Young K, Liu B, Bhuket T, Wong RJ. Lower Likelihood of Post-transplant Graft Failure, Death, and Retransplantation in the Era of Direct-Acting Antivirals. J Clin Exp Hepatol. 2020;10:581-589. [PMID: 33311895 DOI: 10.1016/j.jceh.2020.02.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Narasimman M, Goldberg DS. State Medicaid Restrictions for Direct-Acting Antiviral Therapy Do Not Impact Posttransplant Outcomes of Recipients of Hepatitis C Virus-Viremic Livers. Liver Transpl 2021;27:140-3. [PMID: 32979030 DOI: 10.1002/lt.25902] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Miranda PB, Franco CC, Martinez JMÁ, Ruiz FJP, Bravo MÁG. Comment on "Improvement in Liver Transplant Outcomes From Older Donors: A US National Analysis": Annals of Surgery, Published Online July, 2019. Ann Surg 2021;274:e667-8. [PMID: 31804403 DOI: 10.1097/SLA.0000000000003695] [Reference Citation Analysis]
31 Nakamura T, Shirouzu T. Antibody-Mediated Rejection and Recurrent Primary Disease: Two Main Obstacles in Abdominal Kidney, Liver, and Pancreas Transplants. J Clin Med 2021;10:5417. [PMID: 34830699 DOI: 10.3390/jcm10225417] [Reference Citation Analysis]
32 Aehling NF, Seehofer D, Berg T. [Liver transplantation - current trends]. Dtsch Med Wochenschr 2020;145:1124-31. [PMID: 32791547 DOI: 10.1055/a-0982-0737] [Reference Citation Analysis]
33 Boyarsky BJ, Strauss AT, Segev DL. Transplanting Organs from Donors with HIV or Hepatitis C: The Viral Frontier. World J Surg 2021. [PMID: 33471156 DOI: 10.1007/s00268-020-05924-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Howell J, Majumdar A, Fink MA, Byrne M, McCaughan G, Strasser SI, Crawford M, Hodgkinson P, Stuart KA, Tallis C, Chen J, Wigg A, Jones R, Jaques B, Jeffrey G, Adams L, Wallace MC, Munn S, Gane E, Thompson AJ, Gow P. Turning the Tide on Hepatitis C Virus-Related Liver Transplantation: The Return on Investment in Hepatitis C Virus Treatment in Australia and New Zealand. Liver Transpl 2021. [PMID: 34624175 DOI: 10.1002/lt.26329] [Reference Citation Analysis]
35 Abreu P, Gorgen A, Oldani G, Hibi T, Sapisochin G. Recent advances in liver transplantation for cancer: The future of transplant oncology. JHEP Rep 2019;1:377-91. [PMID: 32039389 DOI: 10.1016/j.jhepr.2019.07.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]